

**Disclosure of Relevant Financial Relationships with Commercial Companies
Fall 2021 SWOG Group Meeting**

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved prior to this program.

A. Financial Disclosures Related to CME Activities and Requirements:

<u>Planner/Faculty Member</u>	<u>Nature of Relationship</u>	<u>Company</u>
Alyce Sophia Adams	No Disclosures	
Manmeet Ahluwalia	Consultant	Bayer, Novocure, Voyager Therapeutics, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen
	Grant/Research Support (Principal Investigator)	Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck
	Stock Shareholder (Self-managed)	Doctible, Mimivax, Cytodyn, MedInnovate Advisors LLC
Syed A. Ahmad	Speaker's Bureau	AbbVie
Sanjay Aneja	Grant/Research Support (Principal Investigator)	NSF, ASCO, NCI
	Other: (must specify)	Emerson Collective (Advisor)
Jennifer Amengual	Speaker's Bureau	Daiichi Sankyo
	Grant/Research Support (Principal Investigator)	Appia Pharmaceuticals
Banu Arun	Grant/Research Support (Principal Investigator)	Research Grant: CPRIT, NCI, Susan Komen Research paid to institution: AbbVie, AstraZeneca, Pharmacia, Invitae
Marie Bakitas	No Disclosures	
Charles Blanke	No Disclosures	
Ruth Carlos	No Disclosures	
Young Chae	Consultant	Myers-Squibb, Biodesix, Tempus, Foundation Medicine, Roche/ Genentech, Counsyl, Neogenomics, Guardant Health, Immuneoncia, Boehringer Ingelheim, Takeda, Pfizer, Lunit
	Speaker's Bureau	Bristol Myers-Squibb, AstraZeneca, Genentech, Lilly Oncology, Guardant Health,Boehringer Ingelheim, Jazz Pharmaceutical, Merck
	Grant/Research Support (Principal Investigator)	Bristol Myers-Squibb, Biodesix, Lexent Bio, Freenome, Abbvie

Morgan Cox	No Disclosures	
Diwakar Davar	Consultant Grant/Research Support (Principal Investigator)	Checkmate Pharmaceuticals, Shionogi, Vedanta Arcus, BMS, Checkmate Pharmaceuticals, CellSight Technologies, Merck, Tesaro/GSK
Lara Davis	Consultant	Daiichi-Sankyo
Frank DeSanto	No Disclosures	
Tiffin Despres	No Disclosures	
J. Nicholas Dionne-Odom	No Disclosures	
Don Dizon	Consultant Grant/Research Support (Principal Investigator)	AstraZeneca, Merck, Clovis, Regeneron, MedImmune, Pfizer BMS (nivolumab, ipilimumab), Kazai (Cantrixil), Tesaro (Rucaprib), Pfizer (Talazoparib)
John Doski	No Disclosures	
Lee Ellis	Consultant Other: (must specify)	Oncohost LTD Fibrogen (Data Monitoring Committee), New Beta Innovation (Data Monitoring Committee)
Harry Erba	Consultant Speaker's Bureau Grant/Research Support (Principal Investigator) Other: (must specify)	AbbVie, Agios, ALX Oncology, Astellas, Celgene/BMS, Daiichi Sankyo, Genentech, GlycoMintetics, Incyte, Jazz, Kura Oncology, Novartis, Takeda, Trillium AbbVie, Agios, Celgene/BMS, Incyte, Jazz, Novartis AbbVie, Agios, ALX Oncology, Amgen, Daiichi Sankyo, Forma, Forty-Seven, Gilead, GlycoMintetics, ImmunoGen, Jazz Macrogenics, Novartis, PTC Chair IRC: Covance/AbbVie; Chair of AML Registry Steering Cmte: Celgene
Jonathan Friedberg	Consultant Other: (must specify)	DSMC: Bayer and Ascerta Patent Royalties (spouse)
Nilanjan Ghosh	Grant/Research Support (Principal Investigator)	Genentech/ Roche
Richard Ha	No Disclosures	
Patrick Hagen	No Disclosures	
Jeremy Harris	No Disclosures	
Norah Lynn Henry	No Disclosures	
Dan Hertz	No Disclosures	
Dawn Hershman	No Disclosures	
Paul Hesketh	No Disclosures	
Siwen Hu-Lieskovan	Consultant	BMS, Amgen, Xencor, Genmab, Regeneron, Astellas
Johanna Horn	No Disclosures	
Melinda Irwin	No Disclosures	

Reshma Jagsi	No Disclosures	
Rebecca Johnson	Consultant Speaker's Bureau Grant/Research Support (Principal Investigator)	Servier Pharmaceuticals (occasional ad hoc consultant) Servier Pharmaceuticals PCORI Engagement award #20242 (2021)-"Video conferences to share strategies on building Adolescent and Young Adult (AYA) oncology councils"
Lisa Kachnic	No Disclosures	
Karen Kelly	Advisory Board Grant/Research Support (Principal Investigator) Other: (must specify)	AbbVie, Amgen, AstraZeneca, Daiichi Sanko, DebioPharm, EMD Serono, GenMab, Genentech, Janssen, Novartis, Regeneron, Sanofi/Genzyme AbbVie, Amgen, Bristol Myers-Squibb, EMD Serono, Genentech, Jounce, Lilly, Regeneron, Sanofi/Genzyme iDMC- AstraZeneca; Author Royalties-UpToDate
Vaishalee Kenkre	No Disclosures	
Robert Krouse	No Disclosures	
Razelle Kurzrock	Consultant Speaker's Bureau Grant/Research Support (Principal Investigator) Stock Shareholder (Self-managed) Other: (must specify)	X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turning Point Therapeutics, TD2/Volastra, Bicara Therapeutics, Inc. Roche Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant IdbyDNA, CureMatch, Inc. (start-up) Board Member: CureMatch, Inc. (start-up), CureMetrix, Inc. (start-up) Co-Founder: CureMatch, Inc.(start-up)
Heinz-Josef Lenz	Consultant Grant/Research Support (Principal Investigator)	Bayer, Merck, Merck KG, Genentech/Roche, Oncocyte, G1 Therapeutics, Jazz Therapeutics NCI, NIH, DOD, SWOG
Michael Lidsky	No Disclosures	
Christopher Lieu	No Disclosures	
Halle Moore	Grant/Research Support (Principal Investigator)	Daiichi-Sankyo, AstraZeneca, Roche/Genentech, Sermonix (all to institution)
Shishir Maithel	No Disclosures	
Monica Mita	No Disclosures	
Elizabeth Mittendorf	Consultant	Scientific advisory board participant for: Exact Sciences, Merck and Roche/ Genentech
Lucia Nappi	No Disclosures	
Marian Neuhouser	No Disclosures	

Etan Orgel	No Disclosures	
Raymond Osarogiagbon	<p>Consultant</p> <p>Speaker's Bureau</p> <p>Grant/Research Support (Principal Investigator)</p> <p>Stock Shareholder (Self-managed)</p> <p>Other: (must specify)</p>	<p>American Cancer Society, Assoc. of Community Cancer Centers, AstraZeneca Eli Lilly, Genentech/Roche, Tryplich Healthcare Part, National Cancer Inst.,</p> <p>Biodesix</p> <p>National Institutes of Health</p> <p>Gilead Sciences, Pfizer, Eli Lilly</p> <p>Founder of Oncobox Device, Inc: Patent – lymph node specimen kit</p>
Mark O'Rourke	No Disclosures	
Sandip Patel	<p>Consultant</p> <p>Grant/Research Support (Principal Investigator)</p>	<p>Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus</p> <p>Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Genocea, Iovance, Merck, Pfizer, Roche/Genentech</p>
Sapna Patel	No Disclosures	
Philip Philip	<p>Consultant</p> <p>Speaker's Bureau</p> <p>Grant/Research Support (Principal Investigator)</p> <p>Other: (must specify)</p>	<p>Daiichi Sankyo, Novartis, Rafeal Pharmaceuticals, Lilly, Merck, Trisalus</p> <p>AstraZeneca, Bayer, Genentech, Incyte, Novartis, Servier</p> <p>Astellas, Bayer, BeiGene, Bristol-Myers Squibb, Corcept Therapeutics, Daiichi Sankyo, Eisai, Gritstone, Incyte, IQVIA Biotech, Merck, Natera, NGM Biopharmaceuticals, Novocure, Pfizer, ED Pharmaceuticals, Syncore, Rafeal, Taiho Oncology, Thyme, Trisalus</p> <p>DSMB: Blueprint Medicines/Committee, DSMB: Erytech Pharma, Advisory Committee: Caris Diagnostics, Advisory Committee: Daiichi Sankyo, Advisory Committee: Ipsen Biopharmaceuticals, Advisory Committee: Merck, Advisory Committee: Novartis, Advisory Committee: Rafeal Pharmaceuticals, Advisory Committee: Incyte, Advisory Committee: IQVIA Biotech, Advisory Committee: QED Pharmaceuticals, Advisory Committee: Pfizer, Advisory Committee: Rafeal, Advisory Committee: Stemline</p>
Katerina Politi	<p>Consultant</p> <p>Grant/Research Support (Principal Investigator)</p> <p>Other: (must specify)</p>	<p>Halda Therapeutics</p> <p>AstraZeneca, Boehringer Ingelheim, Roche</p> <p>IP for patent on T790M testing licensed from MSKCC to MolecularMD</p>
Lajos Pusztai	<p>Consultant</p> <p>Grant/Research Support (Principal Investigator)</p>	<p>Seagen, Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, and Daiichi</p> <p>Susan Komen Foundation, Breast Cancer Research Foundation, NCI, Merck, AstraZeneca, Seagen, Pfizer, Bristol</p>

		Myers Squibb
Scott Ramsey	Consultant Grant/Research Support (Principal Investigator) Other: (must specify)	BMS, Merck, GRAIL, Pfizer FlatIron Health, BMS, Genentech Steering Cmte – AstraZeneca, Pfizer; Ad Board – Bayer; Pharmacy & Therapeutics Cmte for – Premera Blue Cross and Regence Blue Shield
David Rimm	Consultant	Will disclose during presentation
Flavio Rocha	No Disclosures	
Mike Roth	No Disclosures	
Valerie Rusch	Grant/Research Support (Principal Investigator)	Member, steering committee for LCMC3 trial (accrual completed), supported in part by Genentech
Priyanka Sharma	Grant/Research Support (Principal Investigator) Other: (must specify)	Funding to institution: Novartis, Merck, BMS Advisory board participation: AstraZeneca, Merck, Novartis, Sanofi, Gildead,
Ishwaria Mohan Subbiah	No Disclosures	
George Thomas	No Disclosures	
Ian Thompson	Consultant Grant/Research Support (Principal Investigator)	Partners/Harvard University, Profound Medical MagForce
Brian Till	Consultant Grant/Research Support (Principal Investigator) Other: (must specify)	Mustang Bio Juno Therapeutics, Mustang Bio Mustang Bio (patent/royalties)
Lynne I. Wagner	Consultant	Celgene, Inc., Athenex Inc.
Matthew Wieduwilt	Consultant Stock Shareholder (self-managed)	Gilead, Servier Reata
Courtney Wille	No Disclosures	
Eric Zhou	No Disclosures	

B. Financial Disclosures Related to Scientific Activities of SWOG

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<http://swog.org/Visitors/Download/Policies/Policy35.pdf>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.